International Society for Pharmacoepidemiology (EIN 411688677) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1989

Legal Domicile

Principal Officer

Tobias Gerhard

Tax Period

2022-07-01 to 2023-06-30

International Society for Pharmacoepidemiology, founded in 1989, is a community nonprofit that reported $2.4M in total revenue in fiscal year 2022. Revenue surged 188% from the prior year, signaling strong growth momentum. Expenses of $3.0M exceeded revenue, resulting in a 24% operating deficit.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2022)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $2,328,719

Investment Income $56,674

Other Revenue $0

TOTAL REVENUE $2,385,393

Expense Breakdown

Grants Paid $148,360

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $2,667,574

Other Expenses $2,805,399

TOTAL EXPENSES $2,953,759

Year-over-Year Comparison

	2022	2021	Change
Revenue	$2,385,393	$827,522	+1.9%
Expenses	$2,953,759	$891,957	+2.3%
Net Income	$-568,366	$-64,435	+7.8%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

125

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Andrea Margulis	Director	1.00	Director	$0	$0	$0
Hongbo Yuan	Director	1.00	Director	$0	$0	$0
Stanley Edlavitch	Executive Director Emeritus	1.00	Director	$0	$0	$0
Ursula Kirchmayer	Director	1.00	Director	$0	$0	$0
Daniel Prieto-Alhambra	Director	1.00	Director	$0	$0	$0
Yoshiaki Uyama	Director	1.00	Director	$0	$0	$0
Jennifer Lund	Director	1.00	Director	$0	$0	$0
Stine Hasling Mogensen	Director	1.00	Director	$0	$0	$0
Tomoko Kobayashi	Director	1.00	Director	$0	$0	$0
Mette Norgaard	Director	1.00	Director	$0	$0	$0
Jessica Franklin	Director	1.00	Director	$0	$0	$0
Gillian Caughey	Director	1.00	Director	$0	$0	$0
Shirley Wang	Director	1.00	Director	$0	$0	$0
Montserrat Soriano Gabarro	Director	1.00	Director	$0	$0	$0
Jeremy Rassen	Director	1.00	Director	$0	$0	$0
Efe Eworuke	Director	1.00	Director	$0	$0	$0
Lisa Pont	President-Elect	2.00	Officer Director	$0	$0	$0
Vincent Lo Re	Immediate Past President	2.00	Officer Director	$0	$0	$0
Caitlin Knox	VP Finance-Elect	2.00	Officer Director	$0	$0	$0
Tobias Gerhard	President	2.00	Officer Director	$0	$0	$0
James Vrac	Executive Secretary	20.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	No data	No data	No data	No data
2023	$2,385,393	$2,953,759	$3,943,001	$-568,366
2022	$827,522	$891,957	$4,224,312	$-64,435
2021	$911,170	$943,126	$3,912,869	$-31,956
2020	$2,374,699	$1,959,645	$3,709,080	$415,054
2019	$2,032,537	$1,920,082	$4,057,343	$112,455
2018	$1,749,841	$1,834,180	$3,697,146	$-84,339

International Society for Pharmacoepidemiology